Becton, Dickinson and (NYSE:BDX – Get Rating) updated its FY23 earnings guidance on Thursday. The company provided earnings per share (EPS) guidance of $12.07 to $12.32 for the period, compared to the consensus estimate of $11.97. Becton, Dickinson and also updated its FY 2023 guidance to $12.07-$12.32 EPS.
Analyst Upgrades and Downgrades
Several equities analysts recently commented on the stock. Morgan Stanley increased their price objective on shares of Becton, Dickinson and from $290.00 to $295.00 and gave the company an overweight rating in a research note on Friday. William Blair reaffirmed an outperform rating on shares of Becton, Dickinson and in a research note on Friday, November 11th. The Goldman Sachs Group dropped their price target on shares of Becton, Dickinson and from $319.00 to $272.00 and set a buy rating for the company in a research note on Wednesday, November 23rd. Evercore ISI dropped their price target on shares of Becton, Dickinson and to $270.00 in a research note on Wednesday, November 16th. Finally, Cowen dropped their price target on shares of Becton, Dickinson and to $255.00 in a research note on Wednesday, November 16th. Four research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of Moderate Buy and a consensus price target of $275.64.
Get Becton Dickinson and alerts:Becton, Dickinson and Stock Down 1.1 %
NYSE:BDX traded down $2.63 during trading hours on Friday, reaching $245.84. The company had a trading volume of 2,117,712 shares, compared to its average volume of 1,236,927. The company has a quick ratio of 0.63, a current ratio of 1.04 and a debt-to-equity ratio of 0.55. The firm has a market cap of $69.88 billion, a price-to-earnings ratio of 41.81, a P/E/G ratio of 2.23 and a beta of 0.54. The business's 50-day simple moving average is $251.52 and its two-hundred day simple moving average is $244.40. Becton, Dickinson and has a twelve month low of $215.90 and a twelve month high of $280.62.
Becton, Dickinson and (NYSE:BDX – Get Rating) last posted its quarterly earnings results on Thursday, February 2nd. The medical instruments supplier reported $2.98 EPS for the quarter, topping analysts' consensus estimates of $2.68 by $0.30. Becton, Dickinson and had a net margin of 9.16% and a return on equity of 14.47%. The business had revenue of $4.59 billion during the quarter, compared to analysts' expectations of $4.59 billion. During the same period last year, the company posted $3.64 earnings per share. The business's quarterly revenue was down 2.8% on a year-over-year basis. On average, equities analysts expect that Becton, Dickinson and will post 11.94 earnings per share for the current year.Becton, Dickinson and Announces Dividend
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, March 31st. Shareholders of record on Friday, March 10th will be paid a $0.91 dividend. This represents a $3.64 dividend on an annualized basis and a dividend yield of 1.48%. The ex-dividend date of this dividend is Thursday, March 9th. Becton, Dickinson and's dividend payout ratio (DPR) is 61.90%.
Institutional Inflows and Outflows
A number of large investors have recently made changes to their positions in the company. Zions Bancorporation N.A. lifted its position in shares of Becton, Dickinson and by 13.0% during the first quarter. Zions Bancorporation N.A. now owns 504 shares of the medical instruments supplier's stock valued at $134,000 after purchasing an additional 58 shares in the last quarter. Evergreen Capital Management LLC raised its position in Becton, Dickinson and by 0.6% in the first quarter. Evergreen Capital Management LLC now owns 12,238 shares of the medical instruments supplier's stock worth $3,255,000 after acquiring an additional 67 shares during the period. Global Wealth Management Investment Advisory Inc. raised its position in Becton, Dickinson and by 3.1% in the first quarter. Global Wealth Management Investment Advisory Inc. now owns 2,313 shares of the medical instruments supplier's stock worth $615,000 after acquiring an additional 69 shares during the period. Brighton Jones LLC raised its position in Becton, Dickinson and by 8.8% in the first quarter. Brighton Jones LLC now owns 1,383 shares of the medical instruments supplier's stock worth $368,000 after acquiring an additional 112 shares during the period. Finally, Orion Portfolio Solutions LLC raised its position in Becton, Dickinson and by 10.7% in the first quarter. Orion Portfolio Solutions LLC now owns 1,181 shares of the medical instruments supplier's stock worth $314,000 after acquiring an additional 114 shares during the period. 87.08% of the stock is owned by institutional investors.
Becton, Dickinson and Company Profile
(Get Rating)
Becton, Dickinson & Co engages in the development, manufacture, and sale of medical supplies, devices, laboratory equipment, and diagnostic products. It operates through the following segments: BD Medical, BD Life Sciences, and BD Interventional. The BD Medical segment produces medical technologies and devices that are used to help improve healthcare delivery.
See Also
- Get a free copy of the StockNews.com research report on Becton, Dickinson and (BDX)
- Are Penny Stocks Worth it? Should You Invest in Penny Stocks?
- Zimmer Biomet Beats on Earnings, Growth May be Priced In
- AI Software Maker EPAM Boasts Biggest Tech-Sector Rally
- Ford Stock Going Forward After Big Earnings Flop
- Insiders And Institutions Buy Wolverine Worldwide
Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.